<DOC>
	<DOCNO>NCT01075841</DOCNO>
	<brief_summary>This prospective post-marketing surveillance ( PMS ) study collect safety information 600 subject recurrent and/or metastatic squamous cell cancer head neck ( SCCHN ) treat Erbitux final evaluable case . This PMS study request Korean Regulatory Authorities . After approval new indication Korea , requirement investigate 600 subject six year , continue monitor provide information safety toxicity clinical practice .</brief_summary>
	<brief_title>A Post-marketing Surveillance Study Erbitux Combination With Platinum-based Chemotherapy Metastatic/Recurrent Squamous Cell Cancer Head Neck</brief_title>
	<detailed_description>The PMS study plan conduct within 6 year approval date new indication approximately 50 institution Korea . OBJECTIVES Primary objective : - To obtain safety information use Erbitux subject recurrent and/or metastatic SCCHN term frequency severity adverse event ( AEs ) Secondary objective : - To gather clinical efficacy information treatment During PMS period , subject 's background , subject 's medical history ( surgery , anti-cancer treatment ) , Erbitux treatment status , concurrent medication , response evaluation , status reason discontinuation , AEs ( regardless causal relationship Erbitux ) , abnormal result laboratory test collect . The PMS base case treat Erbitux least . Erbitux prescribe recurrent and/or metastatic SCCHN subject accord approve national label routine clinical practice supervision investigator experience use antineoplastic medicinal product . Prior first infusion , subject receive pre-medication antihistamine corticosteroid . The initial dose Erbitux 400 mg/m2 body surface area subsequent weekly dos 250 mg/m2 administer intravenously via in-line filtration infusion pump , gravity drip , syringe pump . The recommended infusion period initial dose 120 minute subsequent weekly dos 60 minute maximum infusion rate exceed 10 mg/min , equivalent 5 ml/min Erbitux 2 mg/ml 2ml/min Erbitux 5mg/mL .</detailed_description>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects eligible Erbitux treatment accord indication national label Erbitux . The national label approve Korea Food &amp; Drug Administration `` Erbitux combination radiation therapy indicate treatment subject metastatic/recurrent SCCHN .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Head neck neoplasm</keyword>
	<keyword>Carcinoma , squamous cell</keyword>
	<keyword>Cetuximab</keyword>
</DOC>